Medically reviewed by Matthew Wosnitzer, MD Complement 3 glomerulopathy (C3G) is a rare kidney disease that is also ...

Medically reviewed by Femi Aremu, PharmD Complement 3 glomerulopathy (C3G) is a rare type of kidney disease. There are two types: C3 glomerulonephritis (C3GN) and dense deposit disease (DDD).C3GN is ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...